07:00 , Jun 3, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Neurology Alzheimer's disease (AD) Aromatase; b-site APP-cleaving enzyme 1 (BACE1) A study in mice suggests that aromatase inhibitors could be useful for treating AD in males. Aromatase converts testosterone to estrogen. In a mouse model...
07:00 , Mar 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Aromatase; NAD(P)H dehydrogenase, quinone 2 (NQO2; QR2) In vitro assays suggest that casimiroin analogs could help treat cancer. Complete...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Company News

Meditrina, AstraZeneca deal

AstraZeneca granted Meditrina exclusive, worldwide rights to IP covering aromatase inhibitors in combination with estrogen and progestin to treat endometriosis. Financial terms were not disclosed. Meditrina's Femathina ( MPI-674 ) is an armoatase inhibitor that...
07:00 , Apr 16, 2007 |  BioCentury  |  Product Development

Thinning the uterine wall

Aromatase inhibitors are used as chronic treatments in postmenopausal women with estrogen-receptive breast cancer. But given their mechanism of action - which is to inhibit the aromatase enzyme that converts certain androgens to estrogen -...
07:00 , Apr 9, 2007 |  BC Week In Review  |  Clinical News

Femathina: Phase II started

Meditrina began the placebo-controlled, U.S. Phase II M001 trial of oral MPI-674 in 68 healthy females. Meditrina Pharmaceuticals Inc. , Ann Arbor, Mich.   Product: Femathina ( MPI-674 )   Business: Genitourinary   Molecular target:...